Cardiogenic Shock Clinical Trials
18 recruiting trials for Cardiogenic Shock. Eligibility criteria explained in plain English.
TrialFinderData lists 18 Cardiogenic Shock clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Early Phase 1: 1.
Research is led by Inova Health Care Services (2), Min-Seok Kim (1), Stanford University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Pulmonary artery catheter (device, 1 trial), followed by Cardiohelp device (VA-ECMO), Heparin.
Track Cardiogenic Shock trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock...
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To...
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with...
BEAT-SHOCK Registry
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It...
Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly...
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic...
A Clinical Events Committee (CEC) will include Cardiac Surgery Professor and chief of cardiac surgery Rose Kelly MD, Professor of Medicine Ganesh Raveendran MD at the University...
An Interventional Left Ventricular Assist System for Cardiogenic Shock
Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling...
Inova Cardiogenic Shock Registry (INOVA SHOCK)
To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus...
Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR
The goal of this clinical trial is to evaluate the feasibility, effectiveness, and safety of pre-emptive left atrial veno-arterial extracorporeal membrane oxygenation (LAVA-ECMO)...
Early Left Ventricular unLoading by Impella vs Intra-aortic Balloon Pump
Over the past decade, VA-ECMO has become the main mechanical support for cardiogenic shock (CS) unresponsive to medical therapy. However, recent studies failed to show any...
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
Pilot Prospective Randomized Unblinded Pragmatic Trial of Pulmonary Artery Hemodynamic Monitoring Following Hospitalization for Cardiogenic Shock
Post-Surgery Extracorporeal Life Support
Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However,...
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction....
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an...
Pharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network...
The goal of this observational study is to understand and describe the epidemiology of cardiogenic shock in Emilia Romagna with a specific focus on outcome stratified by...
Intra-aortic Balloon Counterpulsation (IABC) Compliance
The investigators intend to study how baseline arterial compliance (as defined by stroke volume/pulse pressure) influences the clinical success of intraaortic balloon...
Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE
The goal of this observational study is to learn whether information collected during routine hospital care, together with blood and urine samples, can help doctors better...
Cardiac Power Output in Cardiogenic Shock Patients
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Explore Other Conditions
Frequently Asked Questions
There are currently 18 clinical trials for Cardiogenic Shock, with 18 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Cardiogenic Shock, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Cardiogenic Shock, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.